Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Paxlovid as a potential treatment for long COVID
Matthew W. McCarthy
Expert Opinion on Pharmacotherapy (2023) Vol. 24, Iss. 17, pp. 1839-1843
Closed Access | Times Cited: 12

Showing 12 citing articles:

Comprehensive Review of COVID-19: Epidemiology, Pathogenesis, Advancement in Diagnostic and Detection Techniques, and Post-Pandemic Treatment Strategies
Y.-C. Chung, Ching-Yin Lam, Pak-Hei Tan, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 15, pp. 8155-8155
Open Access | Times Cited: 9
Exploring the Complexities of Long COVID
Jackson Donald, Shymaa E. Bilasy, Catherine Yang, et al.
Viruses (2024) Vol. 16, Iss. 7, pp. 1060-1060
Open Access | Times Cited: 8
Progress in SARS-CoV-2, diagnostic and clinical treatment of COVID-19
Yang Li, Si-Ming Lu, Jia-Long Wang, et al.
Heliyon (2024) Vol. 10, Iss. 12, pp. e33179-e33179
Open Access | Times Cited: 5
Dysautonomia following Lyme disease: a key component of post-treatment Lyme disease syndrome?
Brittany Adler, Tae Hwan Chung, Peter C. Rowe, et al.
Frontiers in Neurology (2024) Vol. 15
Open Access | Times Cited: 4
Challenges and opportunities in long COVID research
Rebecca E. Hamlin, Catherine A. Blish
Immunity (2024) Vol. 57, Iss. 6, pp. 1195-1214
Closed Access | Times Cited: 3
Long COVID management: a mini review of current recommendations and underutilized modalities
Tiffany K. Dietz, Kirsten N. Brondstater
Frontiers in Medicine (2024) Vol. 11
Open Access | Times Cited: 2
Effect of Paxlovid Treatment During Acute COVID-19 on Long COVID Onset: An EHR-Based Target Trial Emulation from the N3C and RECOVER Consortia
Alexander Preiss, Abhishek Bhatia, Leyna Aragon, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
Advances in the Search for SARS-CoV-2 Mpro and PLpro Inhibitors
Marcel Arruda Diogo, Augusto Gomes Teixeira Cabral, Renata Barbosa de Oliveira
Pathogens (2024) Vol. 13, Iss. 10, pp. 825-825
Open Access | Times Cited: 1
Intravenous immunoglobulin as a potential treatment for long COVID
Matthew W. McCarthy
Expert Opinion on Biological Therapy (2023) Vol. 23, Iss. 12, pp. 1211-1217
Closed Access | Times Cited: 4
Lessons learnt from broad-spectrum coronavirus antiviral drug discovery
Andrew A. Bolinger, Jun Li, Xuping Xie, et al.
Expert Opinion on Drug Discovery (2024) Vol. 19, Iss. 9, pp. 1023-1041
Closed Access
Evaluation of the Efficacy of Methylene Blue Administration in SARS-CoV-2-Affected Patients: A Proof-of-Concept Phase 2, Randomized, Placebo-Controlled, Single-Blind Clinical Trial
Beatrice Barda, Bruno Di Mari, Emiliano Soldini, et al.
Scientia Pharmaceutica (2024) Vol. 92, Iss. 4, pp. 56-56
Open Access
Pre-exposure prophylaxis of COVID-19 with tixagevimab/cilgavimab (Evusheld) in 63 rituximab-treated patients with ANCA-associated systemic vasculitis: two-year follow-up results
Т. V. Beketova, N. О. Levina, Yu. A. Uskova, et al.
Rheumatology Science and Practice (2024) Vol. 62, Iss. 5, pp. 465-473
Open Access
Page 1

Scroll to top